Literature DB >> 30310233

Drug repurposing: progress, challenges and recommendations.

Sudeep Pushpakom1, Francesco Iorio2, Patrick A Eyers3, K Jane Escott4, Shirley Hopper5, Andrew Wells6, Andrew Doig7, Tim Guilliams8, Joanna Latimer9, Christine McNamee1, Alan Norris1, Philippe Sanseau10, David Cavalla11, Munir Pirmohamed1.   

Abstract

Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compounds, with potentially lower overall development costs and shorter development timelines. Various data-driven and experimental approaches have been suggested for the identification of repurposable drug candidates; however, there are also major technological and regulatory challenges that need to be addressed. In this Review, we present approaches used for drug repurposing (also known as drug repositioning), discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed to help realize the full potential of drug repurposing.

Entities:  

Mesh:

Year:  2018        PMID: 30310233     DOI: 10.1038/nrd.2018.168

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  143 in total

Review 1.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

Review 2.  Pioneering government-sponsored drug repositioning collaborations: progress and learning.

Authors:  Donald E Frail; Madeleine Brady; K Jane Escott; Alison Holt; Hitesh J Sanganee; Menelas N Pangalos; Chris Watkins; Craig D Wegner
Journal:  Nat Rev Drug Discov       Date:  2015-11-20       Impact factor: 84.694

3.  Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.

Authors:  Dominic A Sloane; Michael Z Trikic; Matthew L H Chu; Maria B A C Lamers; Clive S Mason; Ilka Mueller; Wendy J Savory; David H Williams; Patrick A Eyers
Journal:  ACS Chem Biol       Date:  2010-06-18       Impact factor: 5.100

4.  Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women.

Authors:  N E Rance; W S Young
Journal:  Endocrinology       Date:  1991-05       Impact factor: 4.736

5.  Predicting new molecular targets for known drugs.

Authors:  Michael J Keiser; Vincent Setola; John J Irwin; Christian Laggner; Atheir I Abbas; Sandra J Hufeisen; Niels H Jensen; Michael B Kuijer; Roberto C Matos; Thuy B Tran; Ryan Whaley; Richard A Glennon; Jérôme Hert; Kelan L H Thomas; Douglas D Edwards; Brian K Shoichet; Bryan L Roth
Journal:  Nature       Date:  2009-11-01       Impact factor: 49.962

6.  Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature.

Authors:  Melinda A Mittelman-Smith; Hemalini Williams; Sally J Krajewski-Hall; Nathaniel T McMullen; Naomi E Rance
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

7.  SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.

Authors:  Alexey Tyryshkin; Abhisek Bhattacharya; N Tony Eissa
Journal:  Cancer Res       Date:  2014-04-01       Impact factor: 12.701

8.  Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Julia K Prague; Rachel E Roberts; Alexander N Comninos; Sophie Clarke; Channa N Jayasena; Zachary Nash; Chedie Doyle; Deborah A Papadopoulou; Stephen R Bloom; Pharis Mohideen; Nicholas Panay; Myra S Hunter; Johannes D Veldhuis; Lorraine C Webber; Les Huson; Waljit S Dhillo
Journal:  Lancet       Date:  2017-04-03       Impact factor: 79.321

9.  Understanding multicellular function and disease with human tissue-specific networks.

Authors:  Casey S Greene; Arjun Krishnan; Aaron K Wong; Emanuela Ricciotti; Rene A Zelaya; Daniel S Himmelstein; Ran Zhang; Boris M Hartmann; Elena Zaslavsky; Stuart C Sealfon; Daniel I Chasman; Garret A FitzGerald; Kara Dolinski; Tilo Grosser; Olga G Troyanskaya
Journal:  Nat Genet       Date:  2015-04-27       Impact factor: 38.330

Review 10.  Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds.

Authors:  Hongbin Huang; Guigui Zhang; Yuquan Zhou; Chenru Lin; Suling Chen; Yutong Lin; Shangkang Mai; Zunnan Huang
Journal:  Front Chem       Date:  2018-05-09       Impact factor: 5.221

View more
  757 in total

Review 1.  Déjà vu: Stimulating open drug discovery for SARS-CoV-2.

Authors:  Sean Ekins; Melina Mottin; Paulo R P S Ramos; Bruna K P Sousa; Bruno Junior Neves; Daniel H Foil; Kimberley M Zorn; Rodolpho C Braga; Megan Coffee; Christopher Southan; Ana C Puhl; Carolina Horta Andrade
Journal:  Drug Discov Today       Date:  2020-04-19       Impact factor: 7.851

2.  Validation strategies for target prediction methods.

Authors:  Neann Mathai; Ya Chen; Johannes Kirchmair
Journal:  Brief Bioinform       Date:  2020-05-21       Impact factor: 11.622

3.  A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing.

Authors:  Mahnaz Habibi; Golnaz Taheri; Rosa Aghdam
Journal:  Sci Rep       Date:  2021-04-30       Impact factor: 4.379

4.  Oral Drug Delivery Technologies-A Decade of Developments.

Authors:  G Kaur; M Arora; M N V Ravi Kumar
Journal:  J Pharmacol Exp Ther       Date:  2019-04-22       Impact factor: 4.030

5.  deepDR: a network-based deep learning approach to in silico drug repositioning.

Authors:  Xiangxiang Zeng; Siyi Zhu; Xiangrong Liu; Yadi Zhou; Ruth Nussinov; Feixiong Cheng
Journal:  Bioinformatics       Date:  2019-12-15       Impact factor: 6.937

6.  Key driver genes as potential therapeutic targets in renal allograft rejection.

Authors:  Zhengzi Yi; Karen L Keung; Li Li; Min Hu; Bo Lu; Leigh Nicholson; Elvira Jimenez-Vera; Madhav C Menon; Chengguo Wei; Stephen Alexander; Barbara Murphy; Philip J O'Connell; Weijia Zhang
Journal:  JCI Insight       Date:  2020-08-06

Review 7.  Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity.

Authors:  Gina Wall; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

8.  A ligand-based computational drug repurposing pipeline using KNIME and Programmatic Data Access: case studies for rare diseases and COVID-19.

Authors:  Alzbeta Tuerkova; Barbara Zdrazil
Journal:  J Cheminform       Date:  2020-11-25       Impact factor: 5.514

9.  Soft and Condensed Nanoparticles and Nanoformulations for Cancer Drug Delivery and Repurpose.

Authors:  Wen Yang; Hanitrarimalala Veroniaina; Xiaole Qi; Pengyu Chen; Feng Li; Pu Chun Ke
Journal:  Adv Ther (Weinh)       Date:  2019-10-16

10.  Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19.

Authors:  Carina Conzelmann; Janis A Müller; Lukas Perkhofer; Konstantin Mj Sparrer; Alexander N Zelikin; Jan Münch; Alexander Kleger
Journal:  Clin Med (Lond)       Date:  2020-08-30       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.